Obesity Type 2 Diabetes Mellitus
16
1
4
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.3%
1 terminated out of 16 trials
80.0%
-6.5% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity
Chinese, Overweight or Obesity, Real-World Registry Study
Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy
Impact Of Laparoscopic Sleeve Gastrectomy On Obesity-Related Comorbidities In Patients Over 65 Years
Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy
Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity
ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study
Safety and Tolerability Evaluationof Phascolarcobacterium Faecium
Triglyceride-Glucose and TGI-BMI Indices Compared With HOMA-IR
Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes
Fat Around Heart Arteries as a Measure of Inflammation in Patients With Glycometabolic Disease
CGM Use in Non-insulin Patients With DM2
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)